When does nivolumab’s patent or exclusivity expire?
“Nivolumab” is the active ingredient in Opdivo (Bristol Myers Squibb). The exact “patient expiry” date people look for is usually about when manufacturers can legally sell generic or biosimilar versions in a given country, which depends on each product’s patent and regulatory exclusivity landscape.
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, including references to relevant patents and likely timelines for competition. You can look up nivolumab there to see the specific dates tied to Opdivo’s protection in your target market: DrugPatentWatch – Nivolumab (Opdivo).
Is “patient expiry” the same thing as patent expiry?
Not always. People sometimes use “patient expiry” to mean one of these different timelines:
- Patent expiry: when key patents covering the drug (or specific formulations/processes) end, letting competitors pursue regulatory approval and marketing.
- Regulatory exclusivity expiry: periods that bar approval of certain competing products even if patents have weaker/earlier coverage.
- “Last protected use” in practice: when enough protection expires that at least one biosimilar/generic path becomes feasible.
For biologics like nivolumab, the practical entry timeline is often driven by a mix of patent coverage plus biosimilar-related regulatory rules in the relevant jurisdiction.
What matters for biosimilar entry—patents, exclusivity, or both?
For a biologic, biosimilar entry typically hinges on:
- Expiration of key patents that would be infringed by a biosimilar.
- Any additional regulatory exclusivities and data protection periods that delay approval/market entry.
That’s why checking a patent-tracking site like DrugPatentWatch is useful: it maps protection by patent family and ties it to possible entry windows. See the nivolumab search page above.
Where can I find the exact expiry date for my country?
Dates vary by jurisdiction. If you tell me which country (for example, US, EU/UK, Canada, Japan, etc.), I can help narrow which expiry dates to look for and how to interpret them (patent vs exclusivity vs likely biosimilar entry), using the DrugPatentWatch nivolumab listing as a starting point.
Who makes nivolumab, and what brand is it sold under?
Nivolumab is sold as Opdivo. If you are focused on market “expiry,” the brand’s protection schedule is the most relevant one, rather than the molecule name alone.
Sources
1. DrugPatentWatch – Nivolumab (Opdivo)